贵州省使用脑膜炎球菌多糖疫苗的成本效益分析

发布时间：2018-05-22 15:03

本文选题：脑膜炎球菌多糖疫苗 + 成本效益分析　；参考：《中国疫苗和免疫》2017年04期

【摘要】：目的探讨贵州省脑膜炎球菌多糖疫苗(Meningococcal polysaccharide vaccine,MPV)推广使用和纳入免疫规划后的成本效益。方法抽样调查流行性脑脊髓膜炎(流脑)病例住院、非住院治疗费用、陪护费用以及MPV接种投入经费,计算流脑患病的直接和间接费用、流脑患病造成死亡和伤残的经济损失,以及接种MPV的成本效益比值和产生的净效益。结果贵州省MPV推广使用和纳入免疫规划后,1990-2015年全省预计减少流脑发病94 069例,减少致残13 170例,减少死亡10 710例。每例流脑病例患病后减少社会产值88.65万元。适龄儿童因接种MPV而产生的净效益为102.86亿元,成本效益比值为1∶13.54。结论接种MPV对降低贵州省流脑发病水平效果显著,可产生较好的经济效益。
[Abstract]:Objective to investigate the cost-effectiveness of meningococcal polysaccharide vaccine (MPV) in Guizhou province. Methods A sample of patients with epidemic cerebrospinal meningitis (meningitis) was investigated. The cost of hospitalization, non-hospital treatment, accompanying care and MPV inoculation investment were investigated. The direct and indirect costs of meningitis were calculated, and the economic losses of death and disability caused by meningitis were calculated. And the cost-benefit ratio and net benefit of inoculation with MPV. Results after MPV was popularized and included in immunization program in Guizhou province, 94,069 cases of meningitis, 13,170 cases of disability and 10,710 cases of death were expected to be reduced from 1990 to 2015. The social output value was reduced by 886500 yuan after each case of meningitis became ill. The net benefit of inoculation with MPV was 10.286 billion yuan and the cost benefit ratio was 1: 13.54. Conclusion inoculation of MPV has a significant effect on reducing the level of cerebrospinal meningitis in Guizhou province, and can produce better economic benefits.
【作者单位】：贵州省疾病预防控制中心;
【分类号】：R186;R515.2

【相似文献】